Status | Study |
Recruiting |
Study Name: Safety and Efficacy of JS001 for Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma Condition: Bladder Urothelial Carcinoma Date: 2017-04-06 Interventions: Biological: humanized anti-PD-1 monoclonal antibody humanized anti-PD-1 monoclonal antibody (JS001) is a |
Not yet recruiting |
Study Name: Phase 2 Trial of Nab-paclitaxel Plus S-1 vs Gemcitabine Plus Cisplatin as 1-line Chemotherapy of Patients With Local Advanced and/or Metastatic Transitional Cell Carcinoma of Urothelial Tract Condition: Carcinoma, Transitional Cell Date: 2017-02-09 Interventions: Drug: nanoparticle albumin-bound paclitaxel, S-1 |
Recruiting |
Study Name: A Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Urothelial Carcinoma Condition: Urothelial Carcinoma Date: 2016-08-16 Interventions: Drug: INCB054828 INCB054828 once daily on a 2-weeks-on-therapy and 1-week-off-therapy schedule |
Recruiting |
Study Name: Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Condition: Urothelial Carcinoma Date: 2016-06-17 Interventions: Drug: Atezolizumab Atezolizuma |
Recruiting |
Study Name: The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study Condition: Carcinoma, Transitional Cell Date: 2016-05-29 Interventions: Drug: MitoGel™ instillations Treatment with MitoGel™ once weekly for a total of 6 times; in |
Recruiting |
Study Name: A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma After Surgical Resection [IMvigor010] Condition: Carcinoma, Transitional Cell Date: 2015-05-19 Interventions: Drug: Atezolizumab Atezolizumab will be administered at a dose of 1200 milligrams (mg). |
Recruiting |
Study Name: Study of MPDL3280A in Bladder Cancer Condition: Carcinoma, Transitional Cell Date: 2015-03-04 Interventions: Drug: MPDL3280A Dose Level 1 1 |
Withdrawn |
Study Name: BIBF1120 in Patients With Advanced FGFR3 Mutated,Overexpressed,or Wild Type Urothelial Carcinoma Condition: Urothelial Carcinoma Date: 2014-10-28 Interventions: Drug: BIBF1120 BIBF1120 200 mg two times per day orally |
Active, not recruiting |
Study Name: EGCG Modulate the Cytotoxic Effects of Chemotherapeutic Agents in Human Urothelial Carcinoma Cells Condition: Urothelial Carcinoma Date: 2013-10-24 |
Active, not recruiting |
Study Name: The Role of Pyruvate Kinase M2 in Growth, Invasion and Drug Resistance in Human Urothelial Carcinoma Condition: Bladder Urothelial Carcinoma Date: 2013-10-21 |